Business

mass. movers

Drug maker slides after trial disappoints

Merrimack’s drug testing targeted a type of  ovarian cancer.

istockphoto.com

Merrimack’s drug testing targeted a type of ovarian cancer.

Advertisement

Merrimack Pharmaceuticals Inc., a Cambridge company focused on developing cancer therapies, fell after it reported results from a mid-stage study involving the drug MM-121 in combination with Paclitaxel to treat platinum-resistant or refractory-advanced ovarian cancer. MM-121, being developed with Sanofi, did not meet its primary “endpoint” of improving progression-free survival. There was no statistical difference between MM-121 with Paclitaxel and Paclitaxel alone. Side effects like diarrhea and vomiting were more prevalent in the group taking MM-121.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.